[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligoprogressive-metastatic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligoprogressive-metastatic-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,64,90,120,147,181,207,235,260],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100544368","phase-2-a-randomized-phase-ii-basket-trial-extending-efficacy-of-systemic-therapy-with-local-consolidative-therapy-for-oligoprogressive-metastatic-disease-extend-op-100544368",false,"NCT06367972","A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)","Inclusion Criteria:\n\n* Age ≥18\n* Histologically or cytologically confirmed stage IV cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n* Candidate for LCT (radiation therapy +\u002F- other local therapies such as surgery, ablation, or embolization) to all sites of progressive disease.\n* Progressive disease will be defined as a discrete radiologic lesion that has not received prior local therapy. Progressive disease will be defined as RECIST (v1.1) defined progression from pre-baseline imaging to baseline imaging at time of screening for the trial.\n* Progressive disease must represent an active lesion, which may be defined as the primary tumor site, regional nodal disease, and\u002For distant metastatic sites.\n* Candidate for radiation therapy to at least one site of disease.\n* Between one and five progressive lesions, counted as follows: each lesion (not site) will be counted as one, with the exception of metastatic lymph node stations, which will collectively count as one lesion. Regional nodal stations will be counted as a collective single lesion if oligoprogressive. All progressive lesions must be amenable to local therapy as noted in criterion 4.2.1.5 above.\n* Counting of oligoprogressive nodal disease will be based on nodal chains. A nodal chain will be considered a single metastatic lesion if the presence of that node results in the patient as having M1 disease per the TNM staging system, AJCC version 8.0. In addition, one of the following criteria must be met: a) ≥1 LN meets radiologic criteria for metastatic disease via RECIST 1.1 (short axis ≥15mm), b) pathologic assessment has confirmed the presence of metastatic cancer cells, and\u002For c) the LN exhibits imaging signal characteristic of a metastatic lesion (e.g. FDG avidity, contrast enhancement, etc…). In the event of ambiguity, a study co-Investigator will make a final determination of whether pathologic criteria are met. The following caveats apply:\n* In participants with a LN exhibiting a short axis ≥15mm and who have other diagnoses that can produce enlarged LNs (e.g. indolent CLL, sarcoidosis, etc…) or a prior history of benign enlarged LNs will not be considered to have metastatic disease per the discretion of the treating physician.\n* LN chains that occur bilaterally will be considered separate metastatic sites. For example, left axilla LNs will counted separately from right axilla LNs.\n* The following midline LN chains will be counted as 1 metastatic site: mediastinal, para-aortic, mesenteric.\n* The following bilateral LN chains will be counted as 1 metastatic site for unilateral involvement, and 2 for bilateral for involvement: preauricular, cervical and occipital, supraclavicular, infraclavicular, pectoral, axillary, hilar, epitrochlear and brachial, iliac, inguinal and femoral, popliteal.\n* Baseline imaging must include a scan done within 4 weeks prior to randomization, demonstrating oligoprogressive disease by RECIST (v1.1) criteria compared to pre-baseline imaging.\n* Baseline imaging must be done within 4 weeks prior to randomization, and the following imaging is required: PET\u002FCT scan or CT scan of the chest\u002Fabdomen\u002Fpelvis. MRI may be substituted as indicated (i.e., CT scan of chest plus MRI abdomen\u002Fpelvis). Intracranial imaging is recommended for those histologies\u002Fdisease sites where intracranial restaging is routinely recommended or appropriate as part of staging\u002Frestaging standard-of-care.\n* Pre-baseline imaging must be done 6-16 weeks prior to baseline imaging, and it is recommended to have a comparable imaging modality (matched modalities between pre-baseline and baseline imaging). RECIST v1.1 will be utilized to define any progressive sites of disease, and if between 1 and 5 RECIST-defined progressive sites of disease are identified, participant may be eligible. Non-RECIST-eligible lesions may be eligible if radiographic and\u002For clinical features support this lesion being progressive.\n* Participants referred for the study that require immediate LCT can receive treatment to CNS lesions or other symptomatic lesions prior to randomization, but these lesions will be counted towards the total number of oligoprogressive lesions.\n* Has one of the following 7 histologic types (metastatic disease): colorectal carcinoma (CRC), renal cell carcinoma (RCC), breast cancer, pancreatic cancer, urothelial (bladder) cancer, prostate cancer, and esophageal cancer.\n* Females of childbearing potential must not be breast feeding and must have a negative serum or urine pregnancy test and must agree to use adequate contraception from the time of screening until 3 months after discontinuation of the study medication. Acceptable methods of contraception include total and true sexual abstinence, tubal ligation, hormonal contraceptives that are not prone to drug-drug interactions (IUS Levonorgestrel Intra Uterine System (Mirena), Medroxyprogesterone injections (Depo-Provera)), copper-banded intra-uterine devices, and vasectomized partner. All hormonal methods of contraception should be used in combination with the use of a condom by their sexual male partner. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Women will be considered post-menopausal if they have been amenorrheic for the past 12 months without an alternative medical cause. The following age-specific requirements must also apply: Women \\\u003C 50 years old: they would be considered post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of exogenous hormonal treatments. The levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) must also be in the post-menopausal range (as per the institution). Women ≥ 50 years old: they would be consider post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of all exogenous hormonal treatments, or have had radiation-induced oophorectomy with the last menses \\> 1 year ago, or have had chemotherapy-induced menopause with \\>1 year interval since last menses, or have had surgical sterilization by either bilateral oophorectomy or hysterectomy.\n* Non-sterilized males who are sexually active with a female partner of childbearing potential must use adequate contraception for the duration of the study and 3 month after the last dose of study medication. Adequate contraception methods include: birth control pills (eg combined oral contraceptive pill), barrier protection (eg condom plus spermicide, cervical\u002Fvault cap or intrauterine device), and abstinence. Participants should not father a child for 6 months after completion of the study medication. Participants should refrain from donating sperm from the start of dosing until 6 months after discontinuing the study medication. If male participants wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of the study medication.\n* Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment:\n* Table of Adequate Organ Function Laboratory Values System Laboratory Value Hematological Absolute neutrophil count (ANC) = ≥500 \u002FmcL Platelets = ≥25,000 \u002F mcL Hemoglobin = ≥7 g\u002FdL Hepatic Serum total bilirubin = ≤ 1.5 mg\u002F\u002Fdl (except for subjects with Gilbert Syndrome, who may have total bilirubin \\\u003C3.0 mg\u002Fdl) OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 mg\u002Fdl AST (SGOT) and ALT (SGPT) = ≤ 3 X ULN OR ≤ 5 X ULN for subjects with liver metastases\n\nExclusion Criteria:\n\n* Metastatic effusion (e.g. pleural effusion or ascites). Note that participants with an effusion that is too small to sample will be eligible for the trial.\n* Leptomeningeal disease.\n* Peritoneal carcinomatosis.\n* Cognitively impaired subjects (e.g. inability to sign informed consent.)\n* Any condition that, in the opinion of the investigator, would interfere with the study treatment or interpretation of the study results.\n* Diffuse bone marrow involvement as defined by disease involvement of a BM biopsy from a site that does not have radiologic evidence of a bone metastasis.\n* More than 4 prior lines of systemic therapy to treat metastatic disease.\n* Diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe delivery of radiotherapy.\n* Known psychiatric or substance abuse disorder\u002Fs that would interfere with trial participation.\n* Concurrent (synchronous or metachronous) other primary malignancy that in the opinion of the treating physician team presents a substantial risk to the participant's life as a competing risk of death (against the primary oligoprogressive malignancy being considered for LCT as part of this trial).","ALL","18 Years",{"count":18,"type":19},400,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE2","PHASE3","To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation \\[the removal or destruction of a body part or tissue or its function\\], or embolization \\[a procedure that uses particles, such as tiny gelatin sponges or beads, to block a blood vessel\\]) to all progressive sites of disease can help to control the disease compared with next-line systemic therapy.",[26],"OligoProgressive Metastatic Disease","RECRUITING","2026-06-09",{"date":30,"type":31},"2026-06-11","ACTUAL",{"date":33,"type":31},"2024-06-06",{"date":35,"type":19},"2030-10-10",{"name":37,"class":38},"M.D. Anderson Cancer Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100578620","phase-2-ctdna-guided-curb-for-opd-mnsclc-on-tki-curb-tki-100578620","NCT06813664","ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)","Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer on Tyrosine Kinase Inhibitor","CURB-TKI","Inclusion Criteria:\n\n1. Age 18 or older.\n2. Able to do most daily activities (ECOG 0-2).\n3. Able and willing to sign an informed consent form to join the study.\n4. Metastatic non-small cell lung cancer (NSCLC) with either an EGFR mutation or ALK rearrangement confirmed by imaging and biopsy.\n5. Eligible for second-line therapy or targeted treatment (TKI) if in Group B.\n6. Willing to give a blood sample for ctDNA analysis.\n7. No limit to how many metastatic sites, but up to 5 progressive lesions that do not require immediate treatment.\n8. Prior radiation therapy near progressive lesions is allowed if applicable.\n9. Cancer lesions must be treatable with specific radiotherapy methods (like SBRT or ablative therapy).\n10. Oligoprogressive disease is evaluated independently for each lesion using specific criteria.\n11. Stable brain metastases allowed if asymptomatic and do not require corticosteroids.\n12. Prior treatment with radiation for oligoprogressive lesions is allowed as long as they remain asymptomatic and re-treatment is possible.\n13. Prior non-stereotactic radiation for palliative purposes is allowed, and if the lesion later progresses but is still asymptomatic and does not require immediate therapy, it can count towards the 5 oligoprogressive lesions.\n14. Able and willing to complete quality of life and health utility questionnaires in English, French, or Spanish.\n15. Accessible for treatment and follow-up.\n\nExclusion Criteria:\n\n1. More than 5 extracranial sites of progressive disease.\n2. Pregnant.\n3. Leptomeningeal disease.\n4. Serious health issues that prevent radiotherapy, like ataxia-telangiectasia or scleroderma.\n5. Prior radiation therapy near the progressive lesion that would prevent treatment with SBRT due to exceeding limits of healthy tissue tolerance.\n6. Any psychological, social, or geographic issues that could make it difficult to comply with the study.\n7. Any other condition that the investigator believes makes participation in the study inappropriate.",{"count":49,"type":19},60,[22],"This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.",[53,26],"Metastatic NSCLC - Non-Small Cell Lung Cancer","NOT_YET_RECRUITING","2026-05-21",{"date":57,"type":31},"2026-05-22",{"date":59,"type":19},"2026-06-01",{"date":61,"type":19},"2028-04-01",{"name":63,"class":38},"University Health Network, Toronto",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":20,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":39},"100601567","consolidative-use-of-radiotherapy-to-block-oligoprogression-in-patients-with-metastatic-melanoma-100601567","NCT07112170","Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma","Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma (CURB-Melanoma) - a Phase 2 Clinical Trial","CURB-Melanoma","Inclusion Criteria:\n\n* Age 18 or older\n* ECOG 0-2\n* Willing and able to provide informed consent\n* Metastatic melanoma detected on imaging and clinically confirmed.\n* Treated with first line immunotherapy or BRAF inhibitors.\n* No upper limit to the number of total metastatic sites, but a maximum of ten progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extra cranial.\n* Patients who had any prior radiation therapy near or overlapping with the oligoprogressive sites are allowed to enroll.\n* All sites of oligoprogression that can be safely treated with SBRT or hypofractionated radiotherapy.\n\nExclusion Criteria:\n\n* \\>10 extracranial sites of progressive disease.\n* Pregnancy.\n* Leptomeningeal disease.\n* Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma.\n* Prior radiotherapy near the oligoprogressive lesion precluding SBRT or hypofractionated radiotherapy due to exceeding OAR tolerance.\n* Any psychological, sociological or geographical issue potentially hampering compliance with the study.\n* Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study.",{"count":73,"type":19},52,[75],"NA","This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.",[78,26],"Metastatic Melanoma",[80,81],"stereotactic body radiation therapy (SBRT)","Melanoma","2026-03-03",{"date":84,"type":31},"2026-03-05",{"date":86,"type":31},"2025-07-24",{"date":88,"type":19},"2028-07-24",{"name":63,"class":38},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":97,"minAge":16,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":20,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100587253","stereotactic-radiotherapy-for-oligoprogressive-erher--metastatic-breast-cancer-a-prospective-phase-2-study-oligopro-breast-100587253","NCT06925984","Stereotactic Radiotherapy for Oligoprogressive ER+\u002FHER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)","The Oligopro-Breast Study: Stereotactic Radiotherapy for Oligoprogressive ER+\u002FHER- Metastatic Breast Cancer, a Prospective Phase 2 Study","Inclusion Criteria:\n\n* ECOG performance status 0-2.\n* Histologically confirmed ER+\u002FHER2- MBC.\n* History of polymetastatic disease. Patients with genuine oligometastatic disease and 1-3 oligoprogressive lesions are only allowed if ablative therapy of all metastases is deemed impossible.\n* Under 1st to 2nd systemic treatment line with hormonotherapy and\u002For CDK4\u002F6 inhibitors for at least 6 months before progression.\n* Progressive disease at 1-3 extracranial sites.\n* Ability to treat all progressive lesions locally according to the treating radiation oncologist.\n\nExclusion Criteria:\n\n* Second malignancy if it is not in complete remission.\n* Previous local treatment for oligoprogression under the current systemic treatment line\n* Current progression in a lesion that has been treated with SBRT before and is not amendable for surgery or radiofrequency ablation (RFA).\n* Progressive or newly diagnosed brain metastases. Known brain metastases that have been nonprogressive for at least 6 months, are not an exclusion criterion.\n* Inability to continue the same ST line after local therapy (for example because of toxicity or patient refusal).\n* Pregnancy.\n* Inability to sign the informed consent.","FEMALE",{"count":99,"type":19},48,[75],"The Oligopro-Breast trial is a Phase II study targeting women with ER+\u002FHER2- metastatic breast cancer who have been on endocrine therapy and\u002For CDK4\u002F6 inhibitors for at least 6 months, and show progressive disease at 1-3 extracranial metastases, which are treatable locally. The trial aims to investigate if treating these resistant metastases with SBRT (or other local treatments if SBRT is not possible) can extend the use of the current systemic therapy.\n\nPatients will continue their existing systemic treatment while receiving SBRT on all progressive lesions. If new oligoprogression occurs, SBRT will be performed again. A new systemic treatment line will start if there is polyprogression (more than 3 lesions at once), progression of more than 6 lesions over 12 months, intracranial progression, or lesions that cannot be treated locally.\n\nThe scientific question is whether local treatment of resistant metastases can prolong the effectiveness of ongoing systemic therapy, which is particularly beneficial if the treatment is well-tolerated. The primary objective is to measure the proportion of patients surviving without changing their systemic treatment line at 6 months after SBRT.\n\nThis trial is significant for patients as it explores a method to potentially extend the duration of effective and well-tolerated treatments, offering hope for better management of metastatic breast cancer.",[26],[104,105,106,107,108,109],"Oligoprogression","metastatic breast cancer","CDK4\u002F6 inhibitors","SBRT","SABR","radiotherapy","2026-01-30",{"date":112,"type":31},"2026-02-02",{"date":114,"type":31},"2025-10-30",{"date":116,"type":19},"2030-05-01",{"name":118,"class":38},"Jules Bordet Institute",5,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":20,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":39},"100586713","stereotactic-radiotherapy-versus-palliative-conventional-radiotherapy-for-oligoprogressive-metastatic-cancers-100586713","NCT06918951","Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers","Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers: A Double-Blind Randomized Phase III Trial","Inclusion Criteria:\n\n1. Age 19 or older\n2. Able to provide informed consent\n3. Histologically confirmed solid malignancy (excluding lymphoma or myeloma) with metastatic disease detected on imaging\n4. Biopsy of metastasis at some time prior to enrollment is preferred, but not required\n5. ECOG performance status 0-2\n6. Life expectancy ≥ 6 months\n7. Progression meeting RECIST criteria in up to 5 individual lesions. Progression may be defined as:\n\n   1. Progression of an individual metastasis according to RECIST 1.1 criteria (≥ 20% enlargement of the tumour vs. baseline or nadir, taking as reference the smallest diameter seen prior to starting or during systemic therapy, and associated with a 5 mm minimum increase in size) OR\n   2. Unambiguous development of a new metastatic lesion at least 5 mm in size OR\n   3. Progressive enlargement of a known metastasis on 2 consecutive imaging studies 2-3 months apart with a minimum 5 mm increase in size from baseline.\n   4. A progressing primary tumor is eligible as per the criteria above\n8. If the participant is on systemic therapy at the time of oligoprogression:\n\n   The most recent systemic therapy agent must have been delivered for a total of at least 3 months, with an initial partial response (PR), complete response (CR) or stable disease (SD) prior to the development of oligoprogressive lesions\n9. If the participant is not on systemic therapy at the time of oligoprogression:\n\n   (i.e., \"oligorecurrence\"(1), however, included as \"oligoprogression\" for the purpose of this study protocol):\n10. There must be PR, CR or SD persisting for at least 3 months prior to the development of oligoprogressive lesions\n11. Participants who are not on systemic therapy at the time of oligoprogression must have other site(s) of disease (metastases or primary tumor) that are stable or resolved and have not received definitive treatment (inclusive of surgery, radical doses of radiotherapy including SABR, or ablation) and are not going to receive SABR.\n12. All sites of oligoprogression can be safely treated\n13. Restaging completed within 12 weeks prior to randomization (see section 5.1)\n14. Negative urine pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of radiotherapy start date.\n\nExclusion Criteria:\n\n1. Serious medical comorbidities precluding radiotherapy. These include ataxia-telangiectasia or scleroderma, Crohn's disease in participants where the gastrointestinal (GI) tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy.\n\n   a. For participants with oligoprogressive lesions in the lung or thorax, this includes interstitial lung disease.\n2. Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, provided that the composite plan meets dose constraints herein. For participants treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. A tissue recovery factor may be used in these calculations and if so, must be clearly documented, along with elapsed time from previous radiotherapy, and approved by the local principal investigator.\n3. Current malignant pleural effusion, malignant ascites, or leptomeningeal disease\n4. Inability to treat all sites of oligoprogressive disease\n5. Liver metastases requiring placement of fiducial markers for SABR, as this would compromise successful blinding. Liver metastases are eligible if: 1) they are treated at an institution that offers liver SABR without fiducial markers or 2) pre-existing markers such as surgical clips or calcifications would serve as fiducial markers\n6. Brain metastasis \\> 3.5 cm in size or a total volume of brain metastases greater than 30 cc.\n7. Clinical or radiologic evidence of spinal cord compression. Participants can be eligible if surgical resection has been performed.\n8. Participants with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of \\>12.\n9. Dominant brain metastasis requiring surgical decompression\n10. For participants with liver metastases; moderate\u002Fsevere liver dysfunction (Child Pugh B or C)\n11. Liver metastases located in the \"Biliary no fly zone\" defined for this trial as common biliary track, cystic duct and distal branches (1 cm) + 5 mm\n12. Surgical resection of all oligoprogression metastases (i.e. no lesion available to be treated with SABR)\n13. Pregnant or lactating individuals","19 Years",{"count":129,"type":19},194,[75],"STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.\n\nParticipants, enrolling oncologists, and the statistician will be blinded to trial arm assignment.\n\nIn the control arm, radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression, and the experimental arm will consist of SABR treatment to all sites of oligoprogression.\n\nPrimary Objectives\n\n* To assess the impact of SABR, compared to palliative conventional radiotherapy, on Progression-free survival on next line systemic therapy (PFS-NEST), oncologic outcomes, and Quality of Life (QOL) in participants with 1-5 oligoprogressing lesions.\n* To assess the feasibility of the clinical trial in terms of accrual and success of double-blinding.\n\nSecondary Objectives\n\n* To evaluate and compare the impact of SABR and palliative radiation therapy on the overall survival (OS), progression free survival (PFS), polymetastatic progression-free survival (PPFS);\n* To assess and compare the proportion of participants receiving additional radiation therapy and other metastasis-directed interventions during follow-up between both arms;\n* To compare the impact of SABR and palliative radiation therapy on the time to initiation of the next line of systemic therapy;\n* To identify and compare the anatomic sites of disease progression between the experimental (SABR) and control (palliative radiation) arms;\n* To compare the treatment related toxicity among participants in each arm;\n* To evaluate and compare the quality of life among participants in each arm;\n* To assess the cost-effectiveness of the experimental arm compared to the control arm.",[104,133,26],"Oligometastatic Disease",[108,135,136,137],"Radiotherapy","Quality of life","Metastatic Cancer","2025-12-08",{"date":140,"type":31},"2025-12-15",{"date":142,"type":31},"2025-12-04",{"date":144,"type":19},"2033-06-01",{"name":146,"class":38},"British Columbia Cancer Agency",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":20,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":39},"100562294","phase-2-radiotherapy-in-combination-with-checkpoint-inhibition-for-patients-with-metastatic-kidney-cancer-100562294","NCT06601296","Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer","STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer.","SPARK","Inclusion Criteria:\n\n* Patients must have metastatic ccRCC.\n* Patients must have oligoprogression defined as progression in ≤5 lesions.\n* All oligoprogression lesions must be suitable for radiation.\n* Patients must have at least one site of disease that can be safely injected with IMSA101.\n* Karnofsky Performance Status (KPS) of at least 50%.\n* Age ≥ 18 years.\n* Patients must have adequate organ and marrow function within 14 days prior to study entry.\n* All IMDC risk categories are allowed.\n\nExclusion Criteria:\n\n* Patients with progressive ultracentral\u002Fcentral chest lesions will be excluded",{"count":156,"type":19},15,[22],"To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR\u002FPULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).",[160,26],"Metastatic Renal Cell Carcinoma ( mRCC)",[162,163,164,165,166,167,168,169,153,170,171],"renal","kidney","mrcc","metastatic","cancer","STING","PULSAR","SABr","nivolumab","IMSA 101","2025-11-07",{"date":174,"type":31},"2025-11-12",{"date":176,"type":31},"2025-04-01",{"date":178,"type":19},"2028-10",{"name":180,"class":38},"University of Texas Southwestern Medical Center",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":189,"minAge":16,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":20,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":39},"100587380","phase-2-stereotactic-body-radiotherapy-or-standard-of-care-for-prostate-oligoprogressive-cancer-100587380","NCT06927635","Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer","Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer: a Randomized Phase II Trial","SECURE","Inclusion Criteria:\n\n* Age \\>18 years\n* Able to provide informed consent\n* Histologic diagnosis of prostate adenocarcinoma\n* Castrate Resistance Prostate Cancer\n* Radiographic evidence of \\\u003C10 sites of extra-cranial OP metastatic lesions\n* Receiving any line of ST for \\>3 months\n* All sites of OP disease are amenable to and can be safely treated with SBRT\n* ECOG performance status 0-3\n\nExclusion Criteria:\n\n* Evidence of spinal cord compression\n* Contraindication to radiotherapy","MALE","100 Years",{"count":192,"type":19},75,[22],"This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).",[196,26],"Castrate Resistance Prostate Cancer",[198,80],"systemic therapy","2025-08-29",{"date":201,"type":31},"2025-09-05",{"date":203,"type":31},"2025-07-08",{"date":205,"type":19},"2030-06",{"name":63,"class":38},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":20,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":39},"100580735","phase-3-continuation-of-first-line-therapy-with-radiotherapy-versus-early-switch-to-second-line-therapy-in-oligoprogressive-hcc-100580735","NCT06841172","Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","Continuation of First-line Therapy With Radiotherapy for Oligoprogression Versus Early Switch to Second-line Therapy in Oligoprogressive Hepatocellular Carcinoma (CROSS): a Multi-center, Randomized, Controlled, Open-label, Phase Ⅲ Trial","Inclusion Criteria:\n\n* 1\\. Histological or cytological confirmation of primary hepatocellular carcinoma (HCC), or diagnosis based on the Clinical Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 edition) issued by the National Health Commission of the People's Republic of China.\n* 2\\. BCLC stage C at the time of first-line systemic treatment.\n* 3\\. Oligoprogression must be confirmed by imaging or histopathology during first-line systemic therapy (FLST). The number of oligoprogressive lesions is limited to 1-5, involving no more than 1-3 organs or systems. These lesions may represent either new metastatic sites or progression of pre-existing lesions. In addition, they must fit one of the two classifications defined in the ESTRO-EORTC consensus on oligometastases: repeat oligoprogression or induced oligoprogression. Oligoprogression may occur within intrahepatic lesions. In the case of lymph node progression, each lymphatic drainage region is considered a separate lesion. For example, the para-aortic lymph nodes (number 16a and number 16b) are each counted as separate lymph node regions.\n* 4\\. Patients must have experienced oligoprogression while receiving their current FLST and must not have previously received any other FLST that resulted in disease progression. Additionally, the current FLST must have maintained disease stability (SD) for at least three months prior to the occurrence of oligoprogression. Furthermore, the expected survival time must be ≥6 months.\n* 5\\. Oligoprogressive lesions must be eligible for radiotherapy and should have at least one measurable lesion that meets RECIST v1.1 criteria; Bone metastases without soft tissue formation are eligible but are considered non-measurable lesions; Bone metastases with soft tissue formation that meet RECIST v1.1 measurable criteria are considered measurable lesions.\n* 6\\. Liver function must be assessed as Child-Pugh score ≤7 points.\n* 7\\. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1.\n* 8\\. Participants must be able to understand and voluntarily sign a written informed consent prior to the initiation of any study-specific procedures and must agree to comply with the treatment and follow-up requirements of the study.\n* 9\\. Male or female patients between 18 and 75 years of age.\n* 10\\. Availability of tumor and blood samples for biomarker assessment.\n\nExclusion Criteria:\n\n* 1\\. Patients who received FLST as adjuvant treatment after curative surgery for HCC.\n* 2\\. Tumor progression occurring within 3 months after initiation of FLST.\n* 3\\. Patients with combined hepatocellular-cholangiocarcinoma (cHCC-CC)\n* 4\\. History of grade ≥3 serious adverse events due to FLST.\n* 5\\. Presence of brain, peritoneal or omental metastases with bleeding after FLST.\n* 6\\. Previous radiation therapy to the site of the oligoprogressive lesion.\n* 7\\. Active untreated hepatitis B, defined as HBsAg positive with HBV DNA levels above the upper limit of normal in the participating center's laboratory.\n* 8\\. Oligoprogressive lesions not amenable to radiotherapy.\n* 9\\. Alpha-fetoprotein (AFP) level ≥10,000 ng\u002FmL at the time of oligoprogression.\n* 10\\. Diagnosis of malignancy other than liver cancer within 3 years prior to enrollment (excluding curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, and\u002For carcinoma in situ).\n* 11\\. Currently participating in any interventional clinical research treatment or having received any other investigational drug or investigational device therapy within the last 4 weeks prior to enrollment.\n* 12\\. Presence of autoimmune disease or other conditions requiring long-term steroid use.\n* 13\\. Severe impairment of the heart, lungs, kidneys, or other vital organs, active infections (other than viral hepatitis), or other serious comorbidities that render the patient unable to tolerate treatment.\n* 14\\. known or suspected allergy to any study drug or to any drug related to this study.\n* 15\\. History of organ transplantation\n* 16\\. Pregnant or breastfeeding women\n* 17\\. Any other factor that the investigator believes may affect the enrollment of patients or the evaluation of study results.","75 Years",{"count":216,"type":19},132,[23],"This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at the time of oligoprogression can effectively prolong progression-free survival compared to early switching to second-line systemic therapy in oligoprogressive hepatocellular carcinoma.",[26,220,135,221],"Hepatocellular Carcinoma (HCC)","Systemic Therapy",[223,224,109,225],"oligoprogressive","HCC","first-line systemic therapy","2025-07-31",{"date":228,"type":31},"2025-08-01",{"date":230,"type":31},"2025-07-21",{"date":232,"type":19},"2028-07-01",{"name":234,"class":38},"Shandong Cancer Hospital and Institute",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":189,"minAge":16,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":20,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100595888","phase-2-the-impact-of-metastatic-directed-radiotherapy-mdrt-on-oligoprogressive-castration-resistant-prostate-cancer-crpc-100595888","NCT07038304","The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)","Oligometastatic Directed Radiotherapy for Patients With Castration Resistant Prostate Cancer","OLYMPIAN","Inclusion Criteria:\n\n* Adenocarcinoma of the prostate.\n* mCRPC setting, with testosterone level \\\u003C 50 ng\u002Fdl or 1.7 nmol\u002Fl.\n* Oligoprogressive disease diagnosed on PSMAscan; defined as the progression of pre-existing metastatic disease, and\u002For the appearance of new metastases and\u002For the appearance of a local relapse with a maximum of 3 lesions in total.\n* Patients currently treated with ADT, whether combined with another systemic treatment such as ARTA, chemotherapy.\n* For patients treated with chemotherapy, the course should be completed or stopped before start MORT - In case of treatment with ARTA, a minimal of 3 months response (PSA or clinical response).\n* WHO performance status 0-2.\n* Age \\> = 18 years old.\n* Patiënt should be presented at the multidisciplinary tumor board of the local hospital in which the therapy will be given.\n* Before patiënt registration, written informed consent must be given according to ICH\u002FGCO and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Serum testosterone level \\> 50 ng\u002Fml or \\> 1.7 nmol\u002Fl.\n* Presence of more than 3 progressive\u002Fnew metastatic lesions and\u002For local recurrence (which counts for 1 lesion).\n* Active malignancy other than prostate cancer that can potentially interfere with the interpretation of the trial, except non-melanoma skin cancer or non-invasive urothelial cell carcinoma.\n* Local recurrence in the prostate after previous radiotherapy\n* Previous treatments (RT, surgery) or comorbidities making new treatment with MDRT impossible.\n* Disorder precluding understanding of trial Information or informed consent or signing informed consent.\n* Evidence of PSMA-negative disease.",{"count":244,"type":19},35,[22],"In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones. This will lead to the stage of metastatic castration-refractory prostate can-cer (mCRPC), which is incurable and results in a median overall survival of 2-3 years.\n\nTreatment options for patients with mCRPC include several systemic agents, such as andro-gen receptor-targeted agents (ARTA), chemotherapy (docetaxel, cabazitaxel) and bone-targeting agents (radium- 223). Clinical progression and, to a lesser extent, biochemical pro-gression traditionally imply a switch to the next line systemic treatment (NEST). Within patients with mCRPC, there is a subgroup showing oligo-progression, defined as the progression of up to 3 lesions, including both metastatic and\u002For local relapse. Oligoprogression reflects a heterogeneous treatment response, which, in turn, reflects the heterogeneity of the clonogenic cells that give rise to mCRPC. Retrospective studies suggest that metastasis-directed radiotherapy (MDRT) to these oligoprogressive lesions delayed the need for NEST. Recently, promising results were published on the use of MDRT in the oligopro-gressive mCRPC (omCRPC) setting, with a NEST-free survival (NEST-FS) of 21 months in well selected patients. Currently, in The Netherlands, patients with omCRPC are frequently referred and treated with MDRT, but a clear treatment protocol and inclusion\u002Fselection criteria are missing. Moreover, the exact benefit of MDRT in patients with omCRPC remains unclear, as prospective evi-dence for MDRT in omCRPC is lacking.",[248,26,249,135],"Prostate Cancer (Adenocarcinoma)","Castration Resistant Metastatic Prostate Cancer","2025-06-17",{"date":252,"type":31},"2025-06-26",{"date":254,"type":31},"2025-01-03",{"date":256,"type":19},"2029-01-03",{"name":258,"class":38},"University Medical Center Groningen",2,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":20,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":39},"100556328","phase-3-stereotactic-body-radiotherapy-for-oligo-progression-metastatic-non-small-cell-lung-cancer-100556328","NCT06523673","Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","Stereotactic Body Radiotherapy (SBRT) for Oligo-Progression During First-Line Chemotherapy in Metastatic Non-Small Cell Lung Cancer (OPPRESS):A Randomized, Controlled, Open-label, Multi-Center Phase 3 Study","OPPRESS","Inclusion Criteria:\n\n* Age ≥ 18 years. Gender is not limited.\n* Histologically and\u002For cytologically confirmed stage IV metastatic NSCLC.\n* Eastern Cooperative Oncology Group (ECOG) score of 0-2.\n* Patients who had prior first-line chemotherapy with clinical benefit lasting for ≥3 months.\n* Driver gene-negative NSCLC patients with oligo-progression during first-line chemotherapy combined with Immune Checkpoint Inhibitors (ICI). Driver gene-positive NSCLC patients, such as epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion positivity, are allowed to enroll if oligo-progression occurred during treatment with first-line chemotherapy combined with bevacizumab ± ICI after failure of Tyrosine Kinase Inhibitor (TKI) therapy.\n* Progressive sites were assessed as ≤5 according to RECIST v1.1 criteria combined with positron emission tomography \u002F computertomography (PET\u002FCT), and all were located extracranially. Progressive lymph node lesions are counted by region, with each lymph node region amenable to concurrent SBRT (which may contain multiple progressive lymph nodes) counted as 1 progressive site.\n* All progressive sites should be visible on radiologic imaging and assessed as suitable for SBRT treatment by a radiotherapist.\n* Intracranial progressive lesions and symptomatic lesions can be treated with palliative radiotherapy and local therapy prior to enrollment and are not counted within the oligo-progressive sites.\n* Expected survival time greater than 3 months.\n* Comprehensive examination completed within 28 days prior to enrollment in the study and a complete blood count\u002Fdifferential, collected within 15 days, showing that the patient has normal internal organ function and normal bone marrow function.\n* Negative serum or urine pregnancy test in females of childbearing age within 14 days prior to study enrollment.\n* Patients are willing to provide written informed consent and must be willing to adhere to the prescribed follow-up schedule.\n\nExclusion Criteria:\n\n* Currently participating in an interventional clinical study treatment that may affect this study, or have been treated with another investigational drug or investigational device that may affect this study within 4 weeks prior to first treatment.\n* Pregnant or lactating women.\n* Progression sites deemed unsuitable for SBRT treatment as assessed by radiotherapy specialists.\n* Presence of untreated intracranial metastases or symptomatic progressive sites.\n* History of malignancy other than NSCLC or untreated primary malignancy within the past 3 years.\n* Serious active comorbidities that would interfere with treatment in this study.\n* History or evidence of disease that could interfere with the results of the trial, prevent the subject from participating in the study throughout, abnormal values of treatment or laboratory tests, or other conditions that, in the opinion of the investigator, make enrollment inappropriate.",{"count":269,"type":19},104,[23],"The goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy. The main questions it aims to answer are:\n\nDoes SBRT improve progression-free survival in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy? Does SBRT improve overall survival and quality of life in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy?\n\nResearchers will compare SBRT in combination with standard of care (SOC) and SOC only to see if SBRT works to treat oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy.\n\nParticipants will:\n\nTake SBRT in combination with SOC or SOC only. Visit the clinic for checkups and tests as required by the study. Keep a diary of their symptoms and complete the quality of life assessment questionnaire.",[273,274,26],"Metastatic Non-Small Cell Lung Cancer","NSCLC Stage IV","2024-08-28",{"date":277,"type":31},"2024-08-30",{"date":279,"type":19},"2024-09",{"date":281,"type":19},"2027-09",{"name":283,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]